“…In October 2015, the US Food and Drug Administration (FDA) approved T-VEC (talimogene laherparepvec, Amgen, Thousand Oaks, CA, USA), a herpes simplex virus 1 (HSV-1)-expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), which represents the translational success of oncolytic HSV-1 for the treatment of advanced-stage melanoma 9 . Another replication-competent HSV-1, NV1066, genetically engineered to express enhanced green fluorescent protein (EGFP), has been shown to assist in the detection and killing of primary malignancies in the pleural and peritoneal cavity, as well as in cancer harboring lymph nodes and distant organs 11, 12, 13, 14, 15. Importantly, these studies support NV1066 for both diagnostic and therapeutic applications 12 , 13 , 16, 17, 18, 19, 20.…”